Skip to main content


BTK Inhibitors

BTK inhibitors – do they have a role to play in reducing the impact of COVID-19?

Research amongst WM patients with COVID-19 shows interesting findings.
There is a suggestion that BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib may provide favourable suppression of the immune system resulting in the reduction of inflammatory damage to the lungs due to COVID-19 - the so-called cytokine release syndrome (CRS).

Welcome to our new website!

As part of our ongoing commitment to support people with WM and their families, WMUK are proud to announce the launch of our newly redesigned website for the WM community.

Agile Social Share

Share this page